Overview
- Blood cancer specialist who treats myeloid neoplasm including acute leukemias, myelodysplastic syndrome, myeloproliferative neoplasm, chronic myeloid leukemia.
- Cellular therapy specialist with interests in allogeneic hematopoietic cell transplantation and survivorship care.
- Health services researcher investigating social factors influencing access to and outcomes of treatment for hematologic malignancies.
- Cellular therapy specialist with interests in allogeneic hematopoietic cell transplantation and survivorship care.
- Health services researcher investigating social factors influencing access to and outcomes of treatment for hematologic malignancies.
Current Appointments & Affiliations
Assistant Professor of Medicine
·
2022 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Assistant Professor in Population Health Sciences
·
2024 - Present
Population Health Sciences,
Basic Science Departments
Member of the Duke Cancer Institute
·
2022 - Present
Duke Cancer Institute,
Institutes and Centers
In the News
View All News
Recent Publications
Exploring Perspectives on Feasibility, Challenges, and Support Needs for Chlorhexidine Gluconate (CHG) Bathing in the Outpatient Setting for Hematopoietic Cell Transplant Recipients: A Qualitative Study.
Journal Article Transplant Cell Ther · January 2026 BACKGROUND: Chlorhexidine gluconate (CHG) bathing is recommended for infection prevention in hematopoietic cell transplantation (HCT) patients. As more centers transition HCT care to outpatient settings, understanding patients' perceptions of CHG bathing f ... Full text Link to item CiteImpact of recipient sociodemographic factors on allogeneic transplant conditioning intensity and survival outcomes in myeloid malignancies: A secondary analysis of CIBMTR data
Conference Blood · November 3, 2025 AbstractIntroduction: Sociodemographic factors influence all aspects of the allogeneic hematopoietic cell transplantation (HCT) process. Th ... Full text CitePhase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease
Conference Blood · November 3, 2025 AbstractBackground and Significance: Current therapies for steroid-refractory chronic graft versus host disease (SR-cGVHD) feature limited ... Full text CiteRecent Grants
Abatacept for Omidubicel Transplant
Clinical TrialPrincipal Investigator · Awarded by Gamida Cell Inc. · 2025 - 2030A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Inten
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2030A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (A
Clinical TrialPrincipal Investigator · Awarded by Cullinan Florentine Corporation · 2024 - 2029View All Grants
Education, Training & Certifications
Medical College of Wisconsin ·
2014
M.D.